CD40 and neoplasm: For example, while a CD40 agonist-based regimen was found to induce strong T cell-dependent tumor regression in mice bearing subcutaneous KPC tumors [52,74], this treatment was found to be relatively ineffective in PDAC patients, and in those patients with a partial response, the response was through a T cell-independent mechanism of action [75,76].